Evidence Hub

Effect of romosozumab in premenopausal women with severe osteoporosis and anorexia nervosa

Fujimoto K, Maki N, Hashiba D, Maeyama T, Nakagawa R, Arai H, Ohtori S

Osteoporosis and sarcopenia, 2023

Abstract

OBJECTIVES: This study aims to investigate the effects of romosozumab on bone mineral density (BMD) and bone metabolism.

METHODS: In this retrospective case series, romosozumab was administered to 5 premenopausal female patients with osteoporosis and anorexia nervosa with fragility fractures. BMD and bone turnover marker changes were investigated at 6 months and 1 year after administering romosozumab.

RESULTS: BMD increased and high-turnover bone metabolism decreased 6 months and 1 year after administering romosozumab.

CONCLUSIONS: Romosozumab is useful for treating osteoporosis in patients with anorexia nervosa.

How strong is the evidence?

Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free